With ODI Pharma’s sales during the current calendar year, ODI Pharma reached it’s previously stipulated goal of achieving a substantial market share of more than 10%, resulting in a positive operational result for the shareholders of ODI for the financial year 2023/2024.

ODI Pharma has established a strong strategic presence in Poland through its exclusive collaboration with the NEUCA Group, a leading player in the country’s healthcare distribution sector. NEUCA exclusively sources a range of medicinal cannabis products for their product offerings from ODI Pharma through a long-term exclusive contract. Through its subsidiary, ODI Pharma Polska Sp. z o.o., the Company is therefore well-positioned to achieve comprehensive market coverage in Poland and lay the groundwork for expansion across Eastern Europe.

ODI Pharma’s exclusive agreement with Synoptis Pharma Sp. z o.o., part of the NEUCA Group, further solidifies its market presence. This agreement designates ODI as the exclusive supplier of medicinal cannabis flos products for Synoptis in Poland and 22 other Eastern and Southeastern European markets. This collaboration positions ODI as a key player in the region’s medical cannabis supply chain, reflecting its commitment to long-term growth in Poland and beyond. Consequently, ODI Pharma will increase its target for the market share in the Polish market for the coming quarters.

Poland, legalizing medical cannabis in 2017, has experienced rapid growth in demand, driven by increasing patient numbers and regulatory support. the Polish Główny Inspektor Farmaceutyczny (Chief Pharmaceutical Inspectorate or "GIF") says the estimated annual demand for medical cannabis in Poland has almost doubled. Consequently, GIF recently increased the total amount of medical cannabis permitted to be imported into Poland from the original 6 tonnes to just over 11 tonnes p.a. for the future. Between 2019 and 2023, sales of medical cannabis surged from 26,164 grams to 2,578,777 grams, representing a compound annual growth rate (CAGR) of 214.6%. During the same period, registered patients rose from 1,698 to 90,297, with a CAGR of 189.2%.

Given that the Polish market solely relies on imports for the medical cannabis market, ODI sees itself, given its supply and distribution capacities, very well positioned to increase its market share in the coming quarters.

For more information on ODI Pharma, please contact:

Volker Wiederrich, Chairman, ODI Pharma AB

E-mail: info@odipharma.com  

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.